In spite of these limitations, our study is regarded as a preliminary study for a future prospective study to determine the differential effects of tyrosine-kinase inhibitors on p53 in patients with chronic myeloid leukemia. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.